Theodoros P Vassilakopoulos
Abstract
Hodgkin lymphoma (HL) is considered as a highly curable malignancy, but successful treatment can be associated with significant long-term toxicity. Traditional treatment modalities include chemotherapy, radiotherapy (RT) and salvage chemotherapy with autologous stem cell transplantation (ASCT). The goal of modern treatment is focused on tailoring each patient’s approach according to age, risk of relapse and risk of short- and long-term toxicity.